


https://doi.org/10.1016/j.jtcvs.2018.11.120

Authors have nothing to disclose with regard to commercial support.

**ARTERIAL LACTATE BEFORE INITIATION OF VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION FOR POSTCARDIOGENIC SHOCK IMPROVES POSTIMPLANTATION OUTCOME PREDICTION**

**Reply to the Editor:**

The remark of Formica and colleagues in their letter that the level of arterial lactate after the start of venoarterial extracorporeal membrane oxygenation (VA-ECMO) may also affect short-term survival in patients with refractory postcardiogenic shock (RPCS) contributes to the discussion of the importance of arterial lactate as an overall predictive outcome marker in RPCS. Formica and colleagues refer to their own group’s study of 42 surgical patients who received VA-ECMO for cardiogenic shock. Despite the relatively small number of patients, Formica and colleagues identified the arterial lactate level at 48 hours after VA-ECMO start as the most significant independent risk factor associated with mortality during VA-ECMO (odds ratio, 2.16; 95% confidence interval, 1.13-4.14; \( P = .019 \)). Furthermore, the chosen lactate cut off level of 3 mmol/L (27.0 mg/dL) or greater at 48 hours after VA-ECMO initiation was identified as predictive for 30-day mortality, with a significant difference between survivors and nonsurvivors (54.8% vs 14.3%; \( P = .001 \)). These interesting findings on arterial lactate behavior during VA-ECMO support, from which definite recommendations were not possible because of the limited sample size, were later supported by larger studies specifically focusing on blood lactate levels after VA-ECMO initiation.2-4

In contrast, the aim of our study of 105 patients with RPCS supported with VA-ECMO was specifically to identify factors present before VA-ECMO for postimplantation outcome prediction.5 Lactate levels during the days after VA-ECMO start are among several factors that obviously are not available to consider before VA-ECMO is initiated and thus not of any value for postimplantation outcome prediction before VA-ECMO initiation.

Moreover, Formica and colleagues highlight the importance of further analysis of the relationship between presence of ischemic heart disease (IHD) and changes in arterial lactate levels. Considering our focus on factors before VA-ECMO, we have performed an additional subgroup analysis of the 105 patients included in our study comparing the Kaplan-Meier survival curves with an arterial lactate cutoff level of 10 mmol/L (90.1 mg/dL) or greater in patients with or without IHD (the cutoff level of 10 mmol/L or greater was chosen because it corresponds to a specificity of 91%, implying that a lactate level of 10 mmol/L identified more than 90% of the patients who died in our study population). The curves illustrate that when separating the cohort between patients with and without IHD, an arterial lactate of 10 mmol/L or greater had a significant negative impact on survival compared with an arterial lactate less than 10 mmol/L, both in patients with IHD and in those without IHD, as depicted in Figure 1. Furthermore, the lowest 90-day survival (5%) was seen in patients with a combination of IHD and arterial lactate of 10 mmol/L or greater (Figure 1, A). Conversely, patients with absence of IHD and arterial lactate less than 10 mmol/L had a much higher 90-day survival, 80% (Figure 1, B).

In conclusion, our additional analysis demonstrated that presence of IHD in these critically ill patients had a severe negative impact on 90-day survival compared...
with absence of IHD, especially when IHD was combined with arterial lactate levels of 10 mmol/L or greater before VA-ECMO.

Thomas Fux, MD, PhD
Manne Holm, MD, PhD
Jan van der Linden, MD, PhD

Section of Cardiothoracic Surgery and Anesthesiology
Division of Perioperative Medicine and Intensive Care
Karolinska University Hospital
Stockholm, Sweden

Department of Molecular Medicine and Surgery
Karolinska Institutet
Stockholm, Sweden

LACTATE MONITORING FOR RISK STRATIFICATION IN POSTCARDIOTOMY PATIENTS WITH EXTRACORPOREAL MEMBRANE OXYGENATOR SUPPORT

Reply to the Editor:
Lactate is a useful marker of clinically relevant tissue malperfusion and cellular hypoxia before the development of catastrophic change in cardiovascular status. The importance of postoperative lactate level measurements, not only for monitoring patients after cardiac surgery but to predict when critically ill patients will require extracorporeal membrane oxygenator (ECMO) support as well.1

Hyperlactatemia is known to be associated with adverse outcome with increased mortality and morbidity, and it appears to be related primarily to a state of inadequate perfusion of impaired peripheral microcirculation and end-organ hypoperfusion owing to a low cardiac output. The genesis and pathophysiology of hyperlactatemia are multifactorial in patients with refractory postcardiomyopathy cardiogenic shock. Hyperlactatemia is a result of both higher production and lower clearance due to the pathologic process during complicated cardiac surgery. Delayed clearance of lactate because of nonischemic hepatosplanchnic hypoperfusion may contribute to high lactate levels. The liver takes up approximately 60% of the circulating lactate, and most of that lactate is converted back to pyruvate by the hepatocytes. The kidneys are responsible for 30% of lactate metabolism through gluconeogenesis or complete oxidation; in contrast to the liver, however, the

References

https://doi.org/10.1016/j.jtcvs.2018.12.046